Study Indicates Scleroderma Mortality Rates Being Underestimated PDF Print E-mail
Saturday, 25 May 2013 09:09
Scleroderma patients have a significantly reduced life expectancy that is most likely being underestimated, delegates have heard. Most studies on scleroderma survival are based on prevalent cohorts, where no limit is placed on disease duration at the time of recruitment. This leaves results wide open to “survival bias”.

In a bid to overcome the issue and get to the true figures, Dr Nikpour and colleagues from across Australia evaluated the survival rates of nearly 1,300 scleroderma patients from 13 centres, compared with the general Australian population. Patients were studied as an entire cohort, but also as a separate cohort of patients who had been recruited within 5 years of disease onset.

The figures told a different story. In the whole cohort, there were 27 deaths (15 diffuse and 12 limited disease) over the 8 year study period. Twenty five of these 27 deaths were in the subset of patients with early disease. Ten year survival of patients with diffuse disease in the overall cohort was 90% whereas in the early disease cohort it was 70% -- clear evidence that survival bias was alive and kicking, Dr Nikpour said.

Fifteen of the deaths in the first decade were scleroderma-related and all were caused by either heart or lung manifestations. The remaining 12 deaths were not deemed to be  scleroderma related and most were malignancies.

Overall, the study found that the standard mortality ratios were 8.8 for men and 6.4 for women - figures higher than previously reported, Dr Nikpour said.

“Scleroderma carries substantial mortality. The average standard mortality rate of 6.8 in our Australian patients is one of the highest reported and is comparable to some types of malignancies” Dr Nikpour said. The SMR reported here is considerably higher than the SMR of 1.5 recorded in the South Australian registry, she said.

But there may be a variety of explanations for the discrepancy.  There could be differences in scleroderma case definition, death case ascertainment and survival bias, she said. Nevertheless the results were a “compelling rationale” for establishing a large multinational inception cohort of patients with scleroderma to follow disease outcomes, she concluded.

Source: Rheumatology Update (2013)

 
More articles :

» Donating Kidney Doesn't Shorten Lifespan

A study of over 80,000 American live kidney donors found they were likely to live just as long as people who have two healthy kidneys and that the procedure carries very little medical risk.You can read about the by lead author and transplant...

» Scleroderma Research Foundation To Host Patient Webinar Series

The announced the first in a series of free informational Webinars for people living with and others directly or indirectly affected by the disease. The first Webinar will highlight new clinical trials and results from recent studies.The 2011/2012...

» Jefferson Researchers Identify Mechanism Behind Fibrotic Disorder

Scientists from the of Thomas Jefferson University are now several steps closer to understanding the mechanism behind a novel systemic fibrotic disorder that affects some patients with renal insufficiency who receive imaging contrast agents for...

» A Brief History of Scleroderma

While scleroderma may not be very well known to the average person, investigation reveals it has been around for a long time.Classical ReferencesCases of skin disease similar to scleroderma may be found in the writings of Hippocrates as far back as...

» 7 Tips For Maintaining Healthier Skin In Scleroderma

Scleroderma is a rare, connective tissue disease in which the body’s normal tissue is replaced with thick, dense tissue, due to the overproduction of collagen. Although can affect other parts of the body including the kidneys, hearts, and...

» Role of ACE Inhibitors in Preventing Scleroderma Renal Crisis Remains Unclear

Scleroderma patients on angiotensin-converting enzyme inhibitors at the onset of Scleroderma renal crisis do not appear to have worse outcomes than do those not taking the antihypertensive agents prior to the acute renal function deterioration,...